NovoCure Q2 Revenue Jumps 6 Percent

NovoCure reported Q2 2025 GAAP revenue of $158.8 million, up 6% year-over-year and exceeding analyst estimates, with a narrower GAAP net loss of $0.36 per share. Active patients grew 9.3% to 4,331, driven by new launches in non-small cell lung cancer (NSCLC) and positive Phase 3 results for pancreatic cancer, signaling pipeline expansion. Despite this operational progress, gross margin declined to 74% due to initial launch costs and tariffs, impacting short-term profitability. However, the company's robust $911.5 million cash reserves provide a strong financial buffer for continued investment in new indications and upcoming regulatory filings.

Analysis

NovoCure (NVCR) reported a mixed but strategically coherent second quarter for fiscal 2025, demonstrating successful top-line expansion at the cost of near-term profitability. The company surpassed analyst expectations with GAAP revenue of $158.8 million, a 6% year-over-year increase, driven by a 9.3% rise in active patients to 4,331. This patient growth reflects early commercial traction in newly launched indications like non-small cell lung cancer (NSCLC) and continued strength in its core glioblastoma market. However, this growth incurred significant costs, causing gross margin to contract by 300 basis points to 74% due to higher production expenses for its new HFE array, tariffs, and un-reimbursed launch costs. This pressure filtered down to the bottom line, with a GAAP net loss of $0.36 per share and a negative adjusted EBITDA of $9.9 million, missing the consensus estimate of a positive $1.1 million. The key positive catalyst remains the clinical pipeline, where the PANOVA-3 Phase 3 trial in pancreatic cancer met its primary endpoint, with Premarket Approval (PMA) submissions for this and brain metastases expected later in 2025. The company's substantial cash reserve of $911.5 million provides a critical buffer to fund these strategic investments and absorb ongoing operational losses while it works to unlock these larger market opportunities.

Key Decisions for Investors

• Investors should weigh the company's solid top-line performance and 9.3% patient growth against the persistent drag on profitability, as gross margins are expected to remain in the low 70s for the remainder of 2025.
• Upcoming regulatory filings for pancreatic cancer and brain metastases are the most critical near-term catalysts, and their successful submission and eventual approval are paramount to the long-term investment thesis.
• Monitor the commercial uptake velocity and reimbursement status for new indications like NSCLC, as this will be the primary determinant of when current investments will translate into improved margins and positive cash flow.
• Given the negative adjusted EBITDA, the company's robust $911.5 million cash position should be tracked closely to ensure it provides a sufficient runway to achieve its pipeline milestones without the need for near-term dilutive financing.